Condition: Lung Cancer · Lung Metastases · Sponsor: Vergent Bioscience, Inc.
This is a Phase 3, multi-center, randomized and intrasubject controlled study to evaluate the safety and efficacy of abenacianine for injection, a tumor-targeted, activatable fluorescent imaging agent, to identify cancer using NIR imaging in participants undergoing surgery for cancer in the lung. Approximately 132 partiipants will be enrolled to ensure a minimum of 115 evaluable participants receiving abenacianine and undergoing NIR imaging and a control group of 12 participants who will receive abenacianine but no NIR imaging.
This description comes directly from the study's public registry record.
Brian York · 978-882-1403 · byork@vergentbio.com
Eric Bensen, PhD · 952-479-7496 · ebensen@vergentbio.com
Always discuss trial participation with your own doctor first.
| City of Hope National Medical Center | Duarte, California, United States | Recruiting |
| Hoag Memorial Hospital Presbyterian | Newport Beach, California, United States | Not Yet Recruiting |
| University of Colorado Hospital | Aurora, Colorado, United States | Recruiting |
| Orlando Health Cancer Center | Orlando, Florida, United States | Recruiting |
| University of Michigan | Ann Arbor, Michigan, United States | Recruiting |
| Mayo Clinic | Rochester, Minnesota, United States | Recruiting |
| Hospital of the University of Pennsylvania | Philadelphia, Pennsylvania, United States | Recruiting |
| University of Texas, MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| St. Vincent's Hospital | Fitzroy, Victoria, Australia | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07499674